Scott M. K. Lee, Ph.D.

Scott M. K. Lee, Ph.D., is of counsel in the firm’s Chemical and Life Sciences practice groups. Dr. Lee’s practice focuses on patent portfolio development and client counseling for chemical, biotechnology and pharmaceutical clients. He has experience with a wide range of technologies, including small molecule APIs, formulations, recombinant proteins, antibody derivatives, biofuels, stem cells, transgenic plants and animals, CRISPR-Cas9, CAR T-cells, and medical devices. His practice includes representing clients in Patent Trial and Appeal Board (PTAB) proceedings and representing investors and companies in financings and M&A transactions.

Prior to joining the firm, Dr. Lee was an attorney at one of the largest IP-focused firms in the world and then a partner at a small patent boutique focused on life science clients. With decades of experience working with large international pharmaceutical companies, academic institutions and start-ups, Dr. Lee understands the unique commercial needs of each. He relies on this experience to design patent portfolios tailored to each client’s unique business objectives.

With a deep understanding of the interplay between FDA regulatory frameworks for life science products and patent law, Dr. Lee routinely advises clients on developing and implementing worldwide exclusivity strategies to maximize market share. Dr. Lee has successfully prosecuted patents listed in the FDA’s “Orange Book” for blockbuster products and has assisted start-up clients to create portfolios around product candidates or key company technology, with an eye toward creating valuable patent assets to attract investment or acquisition. 

Education

• Georgetown University Law Center (J.D.)
• Harvard University (Ph.D.)
  • Biochemistry
• University of Chicago (B.A.)
  • Biology

Admissions

• District of Columbia
• Registered to practice before the U.S. Patent and Trademark Office
• U.S. Court of Appeals for the Federal Circuit

Services

• U.S. Patent Procurement (Application Drafting & Prosecution)
• IP Transactions
• PTAB Proceedings
• Start-Up

Technologies

• Chemicals
• Life Sciences